52-WEEK EFFICACY AND SAFETY OF BARISITINIB PLUS METHOTREXATE VERSUS METHOTREXATE MONOTHERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS: A REAL-WORLD COHORT STUDY

While Methotrexate (MTX) remains the first-line treatment for rheumatoid arthritis (RA), inadequate response is common. Barisitinib, a Januskinase inhibitor, has shown efficacy when used in combination with MTX in controlled trials. However, real-world data from smaller cohorts remain limited.